COVID CARDIOLOGYFrom May 2020, Bonus Short - COVID CARDIOLOGY
COVID-19 causes STEMI’s, arrhythmias and myocarditis?!? Emergency medicine and cardiology guru Amal Mattu, MD chats with Mizuho Morrison, DO on the cardiovascular effects of COVID-19. They discuss: the known pathophysiology of how viral infections affect the heart; Review the new consensus …27min 58Amal Mattu, MD and Mizuho Morrison, DO
Aspirin: The Latest LiteratureFrom March 2019, A World of (Bladder) Hurt
What is the deal with aspirin for primary prevention of cardiovascular disease? In this segment, Tom and Steve break down some of the most recent, headline-grabbing articles on this exact subject.10min 27Steve Biederman, MD and Tom Robertson, MD
Paper Chase #3 | Another Cool Cardiology Trial AcronymFrom April 2018, Will You Be My Facebook Friend?
In patients with medically treated angina and severe coronary stenosis, PCI did not increase exercise time any more than placebo did. This can be a game-changer, and shows just how important medical optimization is for our patients with CAD.5min 10Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase #4 - PFO Closure or AC vs. Antiplatelets after CVAFrom March 2018, What’s Your (Code) Status?
Patients who had had a recent cryptogenic stroke attributed to PFO had lower stroke recurrence if assigned to PFO closure combined with antiplatelet therapy than those assigned to antiplatelet therapy alone.7min 19Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase #2 - PFO Closure vs Medical Therapy after CVAFrom March 2018, What’s Your (Code) Status?
In patients with PFO who had a CVA, closing the PFO was associated with a lower rate of recurrent ischemic strokes than medical therapy alone during the study period.4min 20Andrew Buelt, DO and Joe Weatherly, DO
The COMPASS TrialFrom February 2018, The Tragically Sore Hip
This branch of the COMPASS trial examined 3 anticoagulation strategies in patients with “stable atherosclerotic disease”: rivaroxaban 5mg BID, ASA 100mg od + placebo BID, ASA 100 BID + rivaroxaban 2.5 mg BID. Casey’s analysis focused on the ASA groups, not the NOAC alone group. He concludes that …13min 36Casey Parker, MD
Paper Chase #2 - DOACs in Afib and Valvular Heart DiseaseFrom November 2017, Lytes and Bites
High-dose NOACs provide overall efficacy and safety similar in atrial fibrillation patients with or without valvular heart disease. •5min 39Andrew Buelt, DO and Joe Weatherly, DO
When The Tricuspid Valve RegurgitatesFrom September 2017, You Can Do It!!
How many leaflets are in the tricusp….kidding. That’s too easy. Instead, which of the following is not a potential physical finding in severe tricuspid insufficiency.12min 12Jordan Roberts, PA-C
Aortic insufficiency (AKA Aortic Regurg)From July 2017, Be Kind and Enjoy Life15minJordan Roberts, PA-C and Vanessa Cardy, MD
Atrial FibrillationFrom June 2017, Legions of Lesions
Atrial fibrillation is a very common arrhythmia characterized by an irregularly irregular pulse. Evaluation and treatment can be done in the outpatient setting unless the patients is hemodynamically unstable. Anticoagulation to prevent stroke is top priority and this can be done with NOACs or …10min 50Rob Orman, MD, Malcolm Thaler, MD, and Vanessa Cardy, MD
Paper Chase 2 - BNP and NT-proBNP Discharge Thresholds for Acute DHFFrom May 2017, My Gut Biome Told Me So
This study showed that getting patients to a pre-determined BNP level prior to discharge might affect re-admission rates. •6min 16Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 1 - PPI Predicts Heart Failure in Patients with CADFrom May 2017, My Gut Biome Told Me So
In this study, PPI use was associated with a higher risk of CHF and death, but not ischemia. Further research is needed to clarify this relationship.6min 3Andrew Buelt, DO and Joe Weatherly, DO
Paper Chase 4 - ICD ImplantationFrom January 2017, Bones Lose Their Autonomy
Prophylactic ICD implantation in patients with symptomatic systolic heart failure not caused by coronary artery disease was not associated with improved care.3min 51Andrew Buelt, DO and Joe Weatherly, DO
Resistant HypertensionFrom January 2017, Bones Lose Their Autonomy
Rob and Malcolm Thaler discuss evaluation and management of patients with resistant and secondary hypertension. •14min 59Malcolm Thaler, MD and Rob Orman, MD
What Do I Do Next? A Secretary Saves the DayFrom May 2016, The Sexology of Radicular Back Pain
Picking up atypical presentations of ACS is challenging. Mike and Amal discuss a case that the UC receptionist identified and notified the RN.24min 41Amal Mattu, MD, Mike Weinstock MD, Susan Williams, Mizuho Morrison, DO, and Genny Messick, MD
Paperchase 1: Aggressive Blood Pressure Control in the ElderlyFrom June 2015, Hep C Crosses the Borderline!
Aggressive blood pressure control in the elderly may be a game of diminishing returns. •5min 2Andrew Buelt, MD and Joe Weatherly, MD
Introduction - An Update on Asprin for DVT ProphylaxisFrom December 2014, My Anxieties Have Anxieties4min 21Rob Orman, MD and Tom Deloughery, MD
Acute Chest Pain: Part 1From September 2014, Pus and Other Wonders
Classic cardiac chest pain was first described in the 1700s. What have we learned since then? •42min 40Mike Weinstock MD and Rob Orman, MD